Nanosphere Q3 Revenues Plunge 49 Percent on End of Service Contracts

On a conference call, the company's CEO said that Nanosphere has submitted a PMA for its 2C19 assay and plans to submit a new 510(k) submission for its cardiac troponin assay.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.